Last reviewed · How we verify
NCT04001608
Study of Seraprevir in Combination With Sofosbuvir in Chronic Genotype 1 Hepatitis C Virus Infection Patients
Phase 3 trial testing Seraprevir in Hepatitis C Virus Infection in 206 participants. Status unknown.
31 July 2019
Quick facts
| Lead sponsor | Ginkgopharma CO., LTD |
|---|---|
| Phase | Phase 3 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 206 |
| Start date | 17 October 2018 |
| Primary completion | 31 July 2019 |
| Estimated completion | 30 November 2019 |
| Sites | 22 locations across China |
Drugs / interventions tested
- Seraprevir — full drug profile →
- Sofosbuvir — full drug profile →
Conditions studied
- Hepatitis C Virus Infection — all drugs for Hepatitis C Virus Infection →
Sponsor
Ginkgopharma CO., LTD — full company profile →
Who can join
Adults 18 to 75, any sex, with Hepatitis C Virus Infection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study was to assess the safety and efficacy of Seraprevir in combination with sofosbuvir administered for 12 weeks in patients with Hepatitis C (HCV) genotype1. Efficacy was assessed by the rate of sustained viral response (SVR) 12 weeks after the discontinuation of therapy (SVR12).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Antiviral Classification
· 2021
Verify or expand the search:
- PubMed search for NCT04001608
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Seraprevir
Trials testing the same drug.
- NCT04111367 — Study of Seraprevir in Combination With Sofosbuvir in Chronic Genotype 2,3,6 Hepatitis C Virus Infection Patients · Phase 2 · unknown
Other recruiting trials for Hepatitis C Virus Infection
Currently open trials in the same condition.
- NCT06870019 — Hepatitis C Tracker Study · NA · recruiting
- NCT06463912 — Screening for Hepatitis c in People Who Inject Drugs in Armenia-Colombia · recruiting
- NCT06718530 — Characterization of Immune Genotypes and Antibody Profiles to Foster the discoVERY of diagnosticbioMARKERS of Liver Canc · recruiting
- NCT06155006 — Adult Screening for Hepatitis c and Linkage to Treatment in Hospitals in Colombia · recruiting
- NCT06431945 — Early Detection of HCV in Injection Drug Users · recruiting
Other Ginkgopharma CO., LTD trials
Trials by the same sponsor.
- NCT04111367 — Study of Seraprevir in Combination With Sofosbuvir in Chronic Genotype 2,3,6 Hepatitis C Virus Infection Patients · Phase 2 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04001608 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ginkgopharma CO., LTD
- Last refreshed: 28 June 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04001608.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing